The brain circuits underlying tics in Tourette's syndrome (TS) are unknown but thought to involve cortico/amygdalo-striato-thalamo-cortical (CSTC) loop hyperactivity. We previously engineered a transgenic mouse "circuit model" of TS by expressing an artificial neuropotentiating transgene (encoding the cAMP-elevating, intracellular A1 subunit of cholera toxin) within a small population of dopamine D1 receptor-expressing somatosensory cortical and limbic neurons that hyperactivate cortico/amygdalostriatal glutamatergic output circuits thought to be hyperactive in TS and comorbid obsessive-compulsive (OC) disorders. As in TS, these D1CT-7 ("Ticcy") transgenic mice's tics were alleviated by the TS drugs clonidine and dopamine D2 receptor antagonists; and their chronic glutamateexcited striatal motor output was unbalanced toward hyperactivity of the motoric direct pathway and inactivity of the cataleptic indirect pathway. Here we have examined whether these mice's tics are countered by drugs that "break" sequential elements of http://dx
Introduction

CSTC hyperactivity and glutamate in TS and OCD
Tourette's syndrome (TS) is voluntarily suppressible, urgedriven motor and/or vocal tics and repeated complex movements, more prevalent and severe in males than females, and often childhood-onset (Robertson, 2000) and comorbid with obsessive-compulsive disorder (OCD), including the OCspectrum hair and skin picking disorders trichotillomania (TTM) and dermatillomania (DTM) (American Psychiatric Association, 2013) , suggesting these comorbid syndromes involve overlapping or parallel brain circuits. A role for cortical and amygdalar glutamatergic output neurons in eliciting and/or mediating neurogenic tics and compulsions has been proposed McGrath et al., 2000; Carlsson, 2000; Rosenberg et al., 2000; Nordstrom and Burton, 2002; Singer et al., 2010; Milad and Rauch, 2012) . Functional MRI of TS shows primary hyperactivity of excitatory somatosensory, insular and efferent motor output circuits, which elicits premonitory urges and tics (Bohlhalter et al., 2006; Wang et al., 2011) , and secondary hypoactivity of motor-suppressing executive-control circuits (Swerdlow and Sutherland, 2005) . The latter may include depleted or deficient regulatory interneuron populations, including not only cortical inhibitory interneurons but striatal cholinergic interneurons that normally excite striatal "indirect pathway" (IP) medium spiny neurons (MSN) that suppress tics and compulsions, and striatal parvalbumin-positive GABAergic fast-spiking interneurons (FSI) that normally inhibit striatal "direct pathway" (DP) MSN that activate tics and compulsions (Kalanithi et al., 2005; Kataoka et al., 2010; Burguiere et al., 2013; Xu et al., 2015a) . Both TS and OCD are associated with hyperactivity of regional (somatosensory or orbitofrontal) cortical output neurons, as well as impaired sensorimotor gating evidenced by PPI (prepulse inhibition) deficits (Swedo et al., 1992; Breiter et al., 1996; Ziemann et al., 1997; Edgley and Lemon, 1999; Gilbert et al., 2004; Mantovani et al., 2006; Swerdlow and Sutherland, 2006; Ahmari et al., 2012) . Transcranial magnetic stimulation (TMS) confirms that both disorders involve not cortical inhibition but disinhibition (Ziemann et al., 1997; Gilbert et al., 2004; Mantovani et al., 2006) . Reflecting cortical hyperactivity, elevated corticostriatal glutamatergic efflux was observed in OCD (Rosenberg et al., 2000) , and repetitive, optogenetic light-evoked orbitofrontal corticostriatal glutamatergic excitation of striatal MSN causes OClike behavior in mice (Ahmari et al., 2013) . Similarly, monkey and rat stereotaxic drug studies show that disinhibiting sensorimotor corticostriatal glutamate output is essential to generate tic-like behaviors, while inhibiting it is essential to diminish them (Pogorelov et al., 2015) . These data indicate that corticostriatal glutamate can elicit, not just mediate, TS-and OC-like behaviors.
CSTC hyperactivity may originate in some etiologic forms of TS as impairment of inhibitory interneurons (Verkerk et al., 2003; Minzer et al., 2004; Penagarikano et al., 2011) or of inhibitory neurotransmission -including defective histamine neurotransmission causing loss of histaminergic nigrostriatal (as well as cortical) presynaptic inhibition in Hdc (histidine decarboxylase) gene deletion-associated hyperdopaminergic forms of human TS or mouse TS-like orofacial and sniffing stereotypies (Ercan-Sencicek et al., 2010; Karagiannidis et al., 2013; Castellan Baldan et al., 2014; Xu et al., 2015b) . Similarly, diminished DAT (dopamine transporter) (Fox et al., 2013) or MAO-A (monoamine oxidase-A) (Bortolato et al., 2011) trigger hyperdopaminergic tic-like and/or OC symptoms in mice. But even these hyperdopaminergic TS etiologies involve striatal immediate-early gene induction that also depends on coincident glutamate input Castellan Baldan et al., 2014) , suggesting that dopamine (DA) and glutamate co-induce striatal CSTC output to mediate or elicit tics and compulsions. TS and OCD subjects also display striatal desensitization and volumetric damage in response to excess corticostriatal glutamate, excess nigrostriatal DA, and/or defective inhibitory interneurons (Peterson et al., 1993 (Peterson et al., , 1998 Menzies et al., 2008) .
Similarly, a striatal motor pathway imbalance in TS and OCD between motion-suppressing output from DA D2-receptorexpressing (D2þ) striatal IP MSN and motion-activating output from DA D1-receptor-expressing (D1þ) striatal DP MSN, favoring IP inactivity and DP hyperactivity, which was proposed to arise from primary nigrostriatal hyperdopaminergia or striatal interneuron dysfunction (Mink, 2001; Albin and Mink, 2006; Denys et al., 2013; Castellan Baldan et al., 2014) , was earlier proposed, and documented in mice, to arise from chronic hyperactive glutamatergic input to the striatum -where glutamate's excitation of D1þ striatal DP MSN is facilitated by striatonigral DA, but b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 -5 3 its excitation of D2þ striatal IP MSN is counteracted by striatonigral DA . Lastly, hyperglutamatergic CSTC tic circuitry explains why TS drugs work: postsynaptic D2 receptor antagonists (e.g., haldol) excite both D2þ cortical inhibitory interneurons and striatal IP MSN, while clonidine reduces excitatory noradrenergic (NE) input to amygdalar and cortical glutamatergic neurons (Lichter and Jackson, 1996; Campbell et al., 1999b; Nordstrom and Burton, 2002; Minzer et al., 2004 ).
1.2.
Hyperglutamatergic D1CT-7 "Ticcy" mice A causative role for chronic cortical and amygdalar glutamatergic neuron output in TS and OCD was first proposed from analysis of the first genetically engineered mouse model of TSþOCD (and to date the only to exhibit TS-like head and body twitches as well as comorbid OC-like behaviors) -the D1CT-7 "Ticcy" transgenic mouse Nordstrom and Burton, 2002) . As the first transgenic "brain circuit-test," preceding by a decade optogenetic artificial channel transgenes that directly depolarize and fire neurons, Ticcy mice instead express an artificial neuropotentiating transgene that enhances neurons' responsiveness to their own endogenous neurotransmitters. This was achieved by DA D1 receptor (DRD1) gene promotertargeted expression of an artificial exon encoding the exclusively intracellular A1 subunit of cholera toxin (CT) , which physiologically activates any cell type by covalently activating its stimulatory G protein G S , to chronically stimulate adenylate cyclase activity and intracellular levels of the second messenger 3 0 ,5 0 -cyclic adenosine monophosphate (cAMP) (Burton et al., 1991; Zeiger et al., 1997) . Furthermore, D1CT expression in the D1CT-7 ("Ticcy") line of such transgenic mice was regionally restricted to a cortical/limbic subset of brain D1þ neurons, with no expression in striatum. This cortical/ limbic D1þ neuron potentiation induces in D1CT-7 mice voluntarily-suppressible, juvenile-onset tics (Nordstrom and Burton, 2002) and compulsions ; glutamatergically unbalanced striatal DP MSN hyperactivity and IP MSN inactivity that remains sensitive to D2 antagonist reactivation ; increased tic severity in males (Nordstrom and Burton, 2002) ; stress sensitivity ; and alleviation by major TS drug classes (Nordstrom and Burton, 2002; Campbell et al., 1999b ) -thus showing the greatest behavioral homology to TSþOCD of animal models reported to date (Burke and Lombroso, 2004; Pittenger et al., 2011) . Based on the hyperglutamatergic status of the Ticcy mice's cortical circuit (normal mice show slower-onset and calmer pentylenetetrazolekindled cortical seizures, and less-pronounced glutamatergic drug-induced locomotion, whereas neither normal nor Ticcy mice show spontaneous seizures) McGrath et al., 2000) and on the known cortical and limbic excitatory outputs triggered by their potentiated D1þ neurons (which comprise a small, intermediate-layer cortical sheet of somatosensory/insular/piriform D1þ glutamatergic pyramidal output neurons and a cluster of amygdalar intercalated nucleus D1þ GABAergic interneurons, that normally in response to DA respectively trigger glutamatergic excitation of the striatum from deep-layer somatosensory-motor-orbitofrontal cortical pyramidal and amygdalar pyramidal output neurons) (Campbell et al., , 1999c , these D1CT-7 Ticcy mice comprised a direct test of the hypothesis that corticostriatal and/or amygdalostriatal glutamatergic circuit hyperactivity can cause tics and compulsions Carlsson, 2000; Nordstrom and Burton, 2002) . The D1CT-7 model's TS-like behavior and drug responses -and its newly claimed PPI deficits (Godar et al., 2015) -demonstrate its "face validity" as model for TS. Moreover, early objections to its "construct validity" Sutherland, 2005, 2006 ) -namely, that its neuropotentiated "hyperactive" circuits did not concord with then-claimed "hypoactive" circuits in TS; and that it was an "artificial" construct without etiological relevance -have subsequently diminished with the awareness that, first, premonitory urges and tics in TS show hypoactivity only within executive-control circuits, but primary hyperactivity within the same somatosensory, insular and efferent motor output circuits hyperactivated in the mice Bohlhalter et al., 2006; Wang et al., 2011; Church and Schlaggar, 2014) ; and, second, that such transgenic brain circuittesting approaches, including later optogenetic techniques (Ahmari et al., 2013; Ahmari and Dougherty, 2015) , impart knowledge about the circuitry and therapy of TS-and OC-like behaviors irrespective of etiology. Awareness of glutamate's role in eliciting tics and compulsions in D1CT-7 mice (Sah and Sallee, 2002; Burke and Lombroso, 2004; Joel, 2006; Ting and Feng, 2008; Wang et al., 2009; Pittenger et al., 2011; Wu et al., 2012; Ahmari and Dougherty, 2015) has helped inspire clinical studies of this neurotransmitter's role in TS and OCD (Chakrabarty et al., 2005; Singer et al., 2010) ; successful trials of antiglutamatergics for OCD and TTM (Lafleur et al., 2006; Grant et al., 2007 Grant et al., , 2009 ; and trials of a D1 antagonist for TS (Gilbert et al., 2014) and OC-spectrum gambling disorder (Grant et al., 2014) . Identifying pharmacological targets within the Ticcy mice's hyperglutamatergic CSTC "tic-circuit" that can serve as "circuit breakers" may provide new leads in functional neuroanatomy and pharmacotherapy. Here we confirm four such postulated "tic-circuit breaker" drugs alleviate or diminish their tics -a serotonin 5-HT2 a,c receptor antagonist (ritanserin) and a NE alpha-1 receptor antagonist (prazosin) that block corticostriatal and/or amygdalostriatal glutamate output , a presynaptic agmatine/imidazoline I1 receptor agonist (moxonidine) that blocks striatal DP MSN output (Tanabe et al., 2006) , and a presynaptic DA D2 receptor agonist (bromocriptine) that blocks nigrostriatal DA output (Ceccherini-Nelli and Guazzelli, 1994) . This supports the contention that hyperactivity of cortico/amygdalostriatal and cortico/amygdalonigral glutamate output elicits tics, and that drugs capable of interrupting this hyperglutamatergic tic-circuit are prospective pharmacotherapies for neurogenic tics in human TS.
Results
Deep-layer cortical pyramidal glutamatergic output neurons express excitatory serotonin 5-HT2a,c receptors (Sheldon and Aghajanian, 1991; Nestler, 1997; Jakab and Goldman-Rakic, 1998; Aghajanian, 1998, 1999; Aghajanian and Marek, 1999) , suggesting a potential therapeutic role in TS for pure 5-HT2a,c antagonists like ritanserin, which also has anxiolytic activities both clinically and in rodents (Ceulemans et al., 1985; Danjou et al., 1992; Gao and Cutler, 1993) putatively due to its similar inhibition of amygdalar 5-HT2c receptors (Gibson et al., 1994 ) that may similarly reduce excitatory amygdalar glutamatergic output to limbic and orbitofrontal cortices, and to nigrostriatal and striatal motor circuits. The ability of ritanserin to suppress tics at a concentration not inhibitory to normal mouse locomotor activity was tested in Fig. 1 . While the Ticcy D1CT-7 transgenic (Tg) mice show multifold numbers of TS-like twitches compared to control non-transgenic control (C) mice, their tics are restored to control levels by acute ritanserin (1 mg/kg, i.p.) treatment (Fig. 1 , Panel A, black bars). Ritanserin treatment did not significantly decrease the control mice's normal, baseline level of infrequent twitching (Fig. 1 , Panel A, white bars). Nor did ritanserin treatment significantly reduce in either Ticcy or control mice the level of cage midline crossings/15 min, a measure of locomotor activity (Fig. 1, Panel B) . This is consistent with previous reports that this 1 mg/kg i.p. ritanserin dosage in rodents, while psychoactive in reducing anxiety, does not inhibit spontaneous locomotion (Ninan and Kulkarni, 1998) . Our data indicate that acute ritanserin treatment selectively suppresses abnormal ticcing without inhibiting normal, baseline spontaneous locomotor activity. Another drug thought to decrease corticostriatal glutamatergic output is the alpha-1 antagonist, prazosin (Fig. 2) , whose alpha-1 NE receptors were shown to be co-expressed with the 5-HT2a,c receptor targets of ritanserin on deep-layer cortical pyramidal glutamatergic output neurons ). Consequently we tested in Fig. 2 the ability of prazosin to suppress corticostriatal glutamatergic tics, at a concentration reportedly not inhibitory to mouse locomotor activity but capable of psychoactively countering DAdependent anorexia (Wellman and Davies, 1992; Wellman et al., 1997; Cheng and Kuo, 2003) . Like ritanserin, acute prazosin treatment (3 mg/kg, i.p.) treatment of the Ticcy D1CT-7 transgenic (Tg) mice decreased their elevated tic counts to the level of control (C) littermates (Fig. 2, Tic reduction by ritanserin is not associated with reduced locomotion. Data are shown as a bar graph of the mean numberþSEM of cage midline crossings, an assay of locomotion, occurring over 15 min of videotaped observation. Non-significance of all effects and interactions was established by repeated measures ANOVA, which revealed that 1 mg/kg i.p. ritanserin did not alter locomotor activity, indicating that the tic-suppressing effect of ritanserin in Ticcy mice occurs in the absence of general locomotor inhibition or sedation. Statistics: initial repeated measures ANOVA (n ¼8 transgenic, 11 control non-transgenic mice) was performed to establish overall significance on tics or locomotion of genotype effect, drug effect, or genotype x drug interaction, after which individual comparisons of the non-parametrically distributed tic data (see Methods) or the parametrically distributed locomotion data were respectively performed by between-group non-parametric Mann-Whitney U-tests or parametric unpaired 2-tailed Student's t-tests of genotype effects, and within-group non-parametric Wilcoxon Signed Rank tests or parametric paired 2-tailed Student's t-tests of drug effects, with significance of effect on nonparametrically distributed tic counts assumed at tied Po0.05 and on parametrically-distributed locomotor event counts assumed at Po0.05. Abbreviations: Tg (D1CT-7 "Ticcy" transgenic female mice); C (non-transgenic control female mice); Veh (saline vehicle i.p. injection); Rit (1 mg/kg i.p. ritanserin injection); **Po0.01 for between-group (Tg vs. C, Veh) comparison (unpaired Mann-Whitney U-test), þPo0.05 for within-group, between-treatment (Tg, Veh vs. Rit) comparison (paired Wilcoxon Signed Rank test), n ¼ 8 Tg, 11C mice. black bars). Prazosin treatment likewise did not significantly decrease the control mice's normal, baseline level of infrequent twitches (Fig. 2 , Panel A, white bars), nor significantly alter locomotion (cage midline crossings) in either the Ticcy transgenic mice or control mice (Fig. 2 , Panel B). Our data indicate that acute treatment with prazosin selectively suppresses abnormal ticcing without inhibiting normal, baseline spontaneous locomotor activities.
The agmatine/imidazoline-1 agonist moxonidine (Fairbanks and Wilcox, 1999; Zhu et al., 1999; Taksande et al., 2010; Dixit et al., 2014) , a less-sedating, lesshypotensive and less alpha-2 NE receptor cross-specific relative of the TS-drug clonidine, exerts distinct central nervous system actions due to its imidazoline-1 (I-1) receptor specificity: whereas clonidine's presynaptic alpha-2 NE agonist action decreases NE stimulation of anxiogenic amygdalar glutamatergic output to the limbic cortex and striatum (Lichter and Jackson, 1996; Nordstrom and Burton, 2002) , moxonidine, as a presynaptic I-1 receptor agonist that both inhibits striatal DP and IP MSN (striatal direct-and indirectpathway GABAergic output neurons) targeted by glutamate (Tanabe et al., 2006) and reduces glutamate-triggered neurotoxicity (Bakuridze et al., 2009) , may suppress the more distal, striatothalamic-output subcircuits of the CSTC tic circuit. Consequently we tested the ability of acute i.p. moxonidine to block hyperglutamatergic-mediated tics at a 0.5 mg/kg dose sufficient not only for peripheral reduction of blood pressure (Zhu et al., 1999) but also for CNS reduction of drug withdrawal-induced anxiety and endogenous anxietydependent compulsive (marble-burying) behavior in rodents (Taksande et al., 2010; Dixit et al., 2014) (Fig. 3) . Like acute ritanserin and prazosin, acute moxonidine treatment of the Ticcy D1CT-7 transgenic (Tg) mice decreased their elevated tic counts to the level of control (C) littermates ( Non-significance of all effects and interactions was established by repeated measures ANOVA, which revealed that 3 mg/kg i.p. prazosin did not alter locomotor activity, indicating that the tic-suppressing effect of prazosin in Ticcy mice occurs in the absence of general locomotor inhibition or sedation. Statistics: Initial repeated measures ANOVA (n¼7 transgenic, 6 control non-transgenic mice) was performed to establish overall significance on tics or locomotion of genotype effect, drug effect, or genotype x drug interaction, after which individual comparisons of the non-parametrically distributed tic data (see Methods) or the parametrically distributed locomotion data were respectively performed by between-group non-parametric Mann-Whitney U-tests or parametric unpaired 2-tailed Student's ttests of genotype effects, and within-group non-parametric Wilcoxon Signed Rank tests or parametric paired 2-tailed Student's t-tests of drug effects, with significance of effect on non-parametrically distributed tic counts assumed at tied Po0.05 and on parametrically-distributed locomotor event counts assumed at Po0.05. Abbreviations: Tg (D1CT-7 "Ticcy" transgenic female mice); C (non-transgenic control female mice); Veh (saline vehicle i.p. injection); Praz (3 mg/kg prazosin i.p. injection); **Po0.01 for between-group (Tg vs. C, Veh) comparison (unpaired Mann-Whitney U-test), þPo0.05 for within-group, between-treatment (Tg, Veh vs. Praz) comparison (paired Wilcoxon Signed Rank test), n¼ 7 Tg, 6C mice.
suggest that acute treatment with moxonidine, whose imidazoline I-1 receptors are known to localize presynaptically on and inhibit striatal GABAergic output neurons, can suppress cortico/amygdalostriatal glutamate-induced abnormal ticcing without inhibiting normal, baseline spontaneous locomotor activities.
The final candidate "tic circuit breaker" drug we examined was the D2 receptor agonist, bromocriptine (Fig. 4) , which at low doses is selectively presynaptic in its action on striatonigral dopaminergic axon terminals (Ceccherini-Nelli and Guazzelli, 1994) , thus inhibiting nigral dopaminergic efflux onto DA receptor-expressing striatal neurons (which should counter the tic-triggering effect of coincident hyperglutamatergic stimulation of striatal D1þ DP MSN as well as disinhibit glutamatergically stimulated D2þ IP MSN). However, bromocriptine is also known to reduce general locomotor activity as a consequence of its presynaptically inhibiting DA input to the striatum (Jackson et al., 1988) , similar to the effect of typical postsynaptic D2 antagonists (like haloperidol) used for tic and OC-spectrum disorders (Cohen et al., 1992) . Consequently, we examined bromocriptine's ability to diminish not only tics but total locomotion events, which are modulated by the same convergent glutamatergic and dopaminergic inputs to striatal DP and IP MSN that mediate tics and compulsions. At 2 hours post-injection, when in rodents bromocriptine is reported to exert its highest presynaptic D2 agonist effect to inhibit nigrostriatal axonal DA release (Jackson et al., 1988) , the elevated tics in the Ticcy D1CT-7 transgenic (Tg) mice were decreased to the level of untreated control (C) littermates ( Tic reduction by moxonidine is not associated with reduced locomotion. Data are shown as a bar graph of the mean numberþSEM of cage midline crossings, an assay of locomotion, occurring over 15 min of videotaped observation. Nonsignificance of all effects and interactions was established by repeated measures ANOVA, which revealed that 0.5 mg/kg i.p. moxonidine did not alter locomotor activity, indicating that the tic-suppressing effect of moxonidine in Ticcy mice occurs in the absence of general locomotor inhibition or sedation. Statistics: initial repeated measures ANOVA (n¼ 9 transgenic, 5 control non-transgenic mice) was performed to establish overall significance on tics or locomotion of genotype effect, drug effect, or genotype x drug interaction, after which individual comparisons of the non-parametrically distributed tic data (see Methods) or the parametrically distributed locomotion data were respectively performed by between-group non-parametric Mann-Whitney U-tests or parametric unpaired 2-tailed Student's t-tests of genotype effects, and within-group nonparametric Wilcoxon Signed Rank tests or parametric paired 2-tailed Student's t-tests of drug effects, with significance of effect on non-parametrically distributed tic counts assumed at tied Po0.05 and on parametrically-distributed locomotor event counts assumed at Po0.05. Abbreviations: Tg (D1CT-7 "Ticcy" transgenic female mice); C (non-transgenic control female mice); Veh (saline vehicle i.p. injection); Mox (0.5 mg/kg moxonidine i.p. injection); **Po0.01 for between-group (Tg vs. C, Veh) comparison (unpaired Mann-Whitney U-test), þþPo0.01 for within-group, between-treatment (Tg, Veh vs. Mox) comparison (paired Wilcoxon Signed Rank test), n ¼ 9 Tg, 5C mice.
effects by broadly inhibiting baseline locomotor initiation mediated by the striatal subcircuit targeted by both convergent cortical/amygdalar glutamate input and nigral DA input. Such an effect is consistent with the role of presynaptic striatal DA D2
receptors to reduce various DA-dependent motor activities and increase catalepsy in mice (Jackson et al., 1988) . It is also consistent with DA's known role as a modulatory inducer of locomotion both normally and in clinical DA-replacement therapy for parkinsonism; and with parkinsonian side-effects being a clinical side-effect of presynaptic D2 agonist therapeutic drugs (including pergolide and aripiprazole). A slight reduction of total locomotion events was also seen in Ticcy mice upon bromocriptine treatment, but did not reach a significant level (Fig. 4 , Panel B, black bars). Bromocriptine's suppression of both twitches and, to a lesser extent, locomotion, in both normal and Ticcy mice suggests it is acting through a broad, motor-circuit inhibiting "hypodopaminergic" effect. The incidence of horizontal total locomotion events in all untreated or bromocriptine treated mice (Fig. 4, Panel B) was roughly twice their incidence of cage midline crossings (not shown), consistent with prior reports that , justifying individual comparison of bromocriptine's effects on the parametrically distributed locomotion event count data by within-group, paired 2-tailed Student's t-test, which revealed that 5 mg/kg i.p. bromocriptine suppressed locomotion events in control mice, indicating that the tic-suppressing effect of bromocriptine in Ticcy and control mice occurs in conjunction with a general locomotor inhibiting (cataleptic) or sedating effect evident in control mice. Statistics: initial repeated measures ANOVA (n ¼ 8 transgenic, 8 control non-transgenic mice) was performed to establish overall significance on tics or locomotion of genotype effect, drug effect, or genotype x drug interaction, after which individual comparisons of the non-parametrically distributed tic data (see Methods) or the parametrically distributed locomotion data were respectively performed by between-group non-parametric Mann-Whitney U-tests or parametric unpaired 2-tailed Student's t-tests of genotype effects, and within-group non-parametric Wilcoxon Signed Rank tests or parametric paired 2-tailed Student's t-tests of drug effects, with significance of effect on non-parametrically distributed tic counts assumed at tied Po0.05 and on parametrically-distributed locomotion event counts assumed at Po0.05. Abbreviations: Tg (D1CT-7 "Ticcy" transgenic female mice); C (non-transgenic control female mice); À Bromo (15 mins pre-injection); þBromo (5 mg/kg i.p. bromocriptine, 2 h post-injection); *Po0.05 for between-group (Tg vs. C, -Bromo) comparison of genotype effect on nonparametrically distributed tic counts (unpaired Mann-Whitney U-test), þPo0.05 for within-group, between-treatment ( ÀBromo vs. þBromo) comparisons of drug effect on non-parametrically distributed Tg and C tic counts (paired Wilcoxon Signed Rank tests), þþPo0.01 for within-group, between-treatment (C, À Bromo vs. þBromo) comparison of drug effect on parametrically-distributed locomotion event counts (paired 2-tailed Students' t-test), n ¼8 Tg, 8C mice.
locomotor initiations in both control and Ticcy mice represent initiations of extended locomotor sequences Nordstrom and Burton, 2002) . Lastly, the bromocriptine study's Ticcy group exhibits a lower population mean tic count and standard error than in the other drug studies, due to the group's smaller proportion of Ticcy mice with more severe tics.
Because Ticcy mice's symptom severity varies epigenetically between individuals, which is controlled for by using a repeated-measures drug design (see Section 5.6), Ticcy groups' mean tic count and standard error differ between drug studies based on each study's proportion of Ticcy mice with more severe or less severe tics.
Discussion
A proposed hyperglutamatergic "tic circuit"
The D1CT-7 "Ticcy" mouse model of TSþOCD was the first brain "circuit test" of a complex psychomotor disease, created by transgenic neuropotentiation of a molecularly and regionally restricted CSTC circuit element Nordstrom and Burton, 2002) . The CSTC subcircuit chronically potentiated in Ticcy mice is a small population of dopaminoceptive D1þ somatosensory cortical and limbic neurons thought to be hyperactive in human TS and OCD, and known to trigger deep-layer cortical and amygdalar Bromocriptine counters tic circuit as a nigrostriatal DA D2 presynaptic agonist. Symbols: triangles, excitatory glutamatergic pyramidal cortical/amygdalar output neurons; Filled triangles, hyperactivated glutamatergic output neurons (due to D1CT-7 transgene-potentiated excitatory afferents in Ticcy mice or genetic/epigenetic alterations in neurogenic TS); circles, target striatal GABAergic Medium-Spiny (output) Neurons (MSN); Squares, modulatory substantia nigra dopaminergic neurons; rectangular "MOVE-URGE boxes," behaviors excited or inhibited by striatal MSN output; -, move-urge-exciting or striatal neuron-exciting neurotransmission; -|, move-urge-inhibiting or striatal-neuron inhibiting neurotransmission; Thicker arrows, increased neurotransmission; Thicker "MOVE-URGE box," move-urge excitation (e.g., tics, obsessions, compulsions, impulses, cravings, or hallucinations, depending on topographic parallelism of the circuit). Abbreviations: GLU, glutamate (excitatory); DA, dopamine (modulatory); CTX, cortex; AMY, amygdala; STR, striatum; SNc, substantia nigra pars compacta; D1, dopamine D1 excitatory postsynaptic receptors; D2, dopamine D2 inhibitory postsynaptic (left) or presynaptic (middle) receptors; DP, striatal direct pathway (D1-receptor excited, motor/urge-activating striatothalamic) MSN; IP, striatal indirect pathway (D2-receptor inhibited, motion/urge-suppressing striatopallidal) MSN; 5-HT2a,c, serotonin 5-HT2a,c excitatory postsynaptic receptors; alpha-1, norepinephrine alpha-1 adrenergic excitatory postsynaptic receptors; I-1, imidazoline-1 (agmatine) inhibitory presynaptic receptors; RIT, ritanserin; PRAZ, prazosin; MOX, moxonidine; BROMO, bromocriptine.
glutamatergic excitation both of efferent striatothalamic DP and striatopallidal IP MSN subcircuits and of efferent nigrostriatal dopaminergic neuron subcircuits. The D1CT-7 Ticcy model thus represents a test of the effect of chronic, coincident input of excitatory forebrain glutamate and modulatory nigral DA upon striatal output -a "hyperglutamatergic tic-circuit" model (Fig. 5) . This model allows us to compare transient, minimal, and usually non-coincident glutamate and DA striatal inputs associated with normal motor behavior (Fig. 5, Panel A) to chronic, potentiated, and coincident glutamate and DA striatal inputs associated with abnormal TSþOCD-like motor behaviors (Fig. 5, Panel B) ; and allows us to both model (Fig. 5 , Panels C-F) and therapeutically vet new proposed classes of "tic-circuit breaker" drugs.
What is the role of normal transient, minimal, and noncoincident glutamate and DA action on CSTC circuitry and behavior? Without coincident action (Fig. 5, Panel A) , striatal DP MSN (movement-and urge-stimulating, direct-pathway GABAergic output neurons that co-express excitatory glutamate receptors and co-excitatory DA D1 receptors) should respond either to cortical/amygdalar glutamate or to nigral DA by eliciting movements and urges. Meanwhile, striatal IP MSN (movement-and urge-suppressing, indirect-pathway GABAergic output neurons that co-express excitatory glutamate receptors and counter-inhibitory DA D2 receptors) should respond to cortical/amygdalar glutamate by suppressing movements and urges, but to nigral DA by eliciting them. Tonic, baseline levels of DA in the striatum are thus likely needed to block excitation of movement-suppressing IP MSN and permit excitation of movement-exciting DP MSN by cortical/amygdalar fast-acting glutamatergic triggers of voluntary movements and urges. Cortical GABAergic interneurons' inhibitory "executive control" will in turn limit the expression of such glutamatergic triggers of voluntary movements and urges unless cortical DA rises to the level of inhibiting these D2þ cortical GABAergic interneurons and potentiating the D1þ cortical glutamatergic output neurons. In this regard, the seeming paradox of glutamatergic psychomotor induction by NMDA glutamate receptor antagonists like PCP is thought to be due to these drugs primarily inhibiting either striatal D2þ IP MSN that suppress motion and urges, or cortical D2þ GABAergic interneurons that suppress corticostriatal glutamate output to striatal NMDA and non-NMDA (e.g., AMPA) glutamate receptors Homayoun and Moghaddam, 2007) .
What then, is the role of abnormal chronic, potentiated, and coincident glutamate and DA action on CSTC circuitry and behavior? This circuit state could originate in TS etiologically either from excessive DA (exciting striatal MSN and D1þ cortical-limbic neuron glutamate output), excessive glutamate (exciting striatal MSN and nigrostriatal DA output), or insufficient GABA (disinhibiting D1þ cortical-limbic neuron glutamate output and striatal MSN). But regardless of etiology, we propose that when such chronic cortical/limbic glutamatergic neuron hyperactivity does occur, the convergence of its hyperglutamatergic input to striatal circuits and of its parallel hyperglutamatergic-inducible nigral DA input to those same striatal circuits will elicit chronic tics and urges, by chronically unbalancing those striatal circuits in favor of tic induction via striatal DP MSN (Fig. 5, Panel B) . This "tic circuit" model is based on a prior "cortical/limbic glutamatergic neuron (CGN) hyperactivity" model of tics and compulsions Carlsson, 2000; Rosenberg et al., 2000; Nordstrom and Burton, 2002) , refined to add corticonigral glutamate excitation of nigrostriatal DA input Denys et al., 2013) .
The mechanism by which chronic glutamate is proposed to unbalance striatal circuit output, causing tics and urges, relies on triggering such coincident glutamate and DA striatal input (Fig. 5, Panel A vs. B) : first, cortical/amygdalar glutamate excites both the movement/urge-activating GABAergic striatal direct-pathway (STR DP) MSN and the nigral DA neurons that co-excite these same STR DP MSN (which co-express excitatory DA D1 receptors). Second, the otherwise counterbalancing cortical/amygdalar glutamate excitation of movement/urge-suppressing GABAergic striatal indirect-pathway (STR IP) MSN (which co-express inhibitory DA D2 receptors) is inhibited by the glutamatergically-excited nigrostriatal DA input.
Alternatively, chronic glutamate-initiated DA inhibition of STR IP MSN could also occur by a pharmacodynamic mechanism that would not require glutamatergic excitation of nigrostriatal DA input : Chronic forebrain glutamatergic hyperexcitation of the STR IP MSN could instead trigger their inhibitory D2 receptors to pharmacodynamically cross-supersensitize to even normal, tonic levels of nigral DA input (Wolf et al., 1996) , which would allow even tonic DA to counter STR IP MSNs' over-excitation by glutamate. But either chronic glutamate-initiated mechanism would still unbalance the tic/urge-triggering STR DP and tic/ urge-suppressing STR IP subcircuits in favor of chronic STR DP hyperactivity causing chronic tics and urges.
Given this "hyperglutamatergic tic circuit" where glutamate and DA synergize at the striatal direct pathway to elicit tics, but antagonize each other at the striatal indirect pathway to fail to suppress tics, the mechanisms by which the four tested "circuit-breaker" drugs would then act on this tic circuit to alleviate or suppress tics are diagrammed (Fig. 5 , Panel B vs. Panels C-F):
First, ritanserin (Fig. 5 , Panel C) and prazosin (Fig. 5, Panel D) antagonize different -but co-expressed -excitatory receptors (respectively, serotonin 5-HT2a,c and alpha-1 NE receptors) located on the deep-layer cortical pyramidal output neurons that glutamatergically excite the striatum and substantia nigra. Prazosin may also inhibit amygdalar glutamate output to striatal and nigral targets, as well as to the limbic cortex. Their blocking cortico/amygdalostriatal and cortico/ amygdalonigral hyperglutamatergic output would thus "circuit-break" these neurons' chronic glutamatergic excitation of their target striatal and nigral neurons, alleviating tics. Moxonidine (Fig. 5 , Panel E) acts more distally on this CSTC circuit loop, upon imidazoline I-1 autoreceptors on the target striatal GABAergic DP MSN and IP MSN themselves, presynaptically inhibiting the striatothalamic output of the glutamatergically-hyperactivated STR DP MSN that would otherwise elicit tics. Bromocriptine (Fig. 5, Panel F) , under experimental conditions where it selectively acts as a presynaptic D2 autoreceptor agonist on nigrostriatal DA neurons, causes "hypodopaminergia" -thus inhibiting the D1þ STR DP MSN that stimulate tics and disinhibiting the D2þ STR
IP MSN that suppress tics. Bromocriptine reportedly also nondopaminergically inhibits glial glutamate release from GLT1 reverse transport (Shirasaki et al., 2010) , hence might also suppress tics by reducing cortical or striatal perisynaptic glutamate concentrations. However, bromocriptine's unique suppression of normal mouse locomotion in our study is more consistent with a hypodopaminergic (parkinsonian) mechanism of action. Overall, the effectiveness of these four classes of drugs in either selectively alleviating tics (i.e., ritanserin, prazosin, moxonidine) or less selectively suppressing both tics and locomotion (i.e., bromocriptine) undergirds the potential validity of this forebrain hyperglutamatergic circuit model of neurogenic tics and urges.
Clinical implications
What is the therapeutic potential of these four "tic circuitbreakers" in treating human TS and its comorbid OC symptoms? Our experiments predict that these four drugs might acutely alleviate tics in TS and in TSþOCD. But one limitation of our study is that it cannot similarly predict their efficacy against OC symptoms in TSþOCD or in OC disorders, because we cannot directly assay acute, short-term drug effects on the Ticcy mice's complex repertoire of compulsions, which must be monitored across long-term time-sampling or observation windows. Nor can we chronically administer these drugs to the Ticcy mice, due to the interpretive confound of the Ticcy mice's extreme anxiety in response to anxiogenic stressors McGrath et al., 1999a McGrath et al., , 1999b , which includes repeated drug injections or surgical implantation. A second limitation of our study is that it is based only on the analysis of tics in female Ticcy mice rather than in both genders: due to their anxiogenic behavior and TTM/DTM-like commensal (as well as self-directed) over-grooming compulsions, females of the D1CT-7 transgenic strain mate and raise pups poorly, necessitating our use of Ticcy males to breed with control females to maintain the colony, while Ticcy females are retained for drug studies (see Section 5.1). Hence our conclusions can only be formally drawn for tics as manifested in Ticcy females -although, as in human TS (Robertson, 2000) , their ticcing is only less severe than Ticcy males' but otherwise indistinguishable (Nordstrom and Burton, 2002) . Apart from these experimental limitations, the parallelism and overlap of CSTC circuits mediating the premonitory urges preceding tics and compulsions -which likely underlies their frequent co-presentation (Frankel et al., 1986 ) -does permit some predictions of these drugs' potential efficacy for both disorders, based on our and others' experimental data: First, ritanserin's acute alleviation of Ticcy mice's tics suggests human tics may similarly respond not just to "mixed" 5-HT2/D2 antagonists, like the atypical neuroleptics risperidone (Bruun and Budman, 1996) and ziprasidone shown to be effective in TS pilot studies, but also to "pure" 5-HT2 antagonists like ritanserin. So far ritanserin has been used in humans to treat anxiety (Ceulemans et al., 1985; Barone et al., 1986; Danjou et al., 1992) , based on its 5-HT2c-antagonist-mediated suppression of amygdalar and "limbic cortex" glutamatergic output (Gibson et al., 1994 ). Yet ketanserin -a ritanserin-related, non-anxiolytic, hypotensive antagonist of both 5-HT2a and, weakly, alpha-1 NE receptors (Hosie, et al., 1987; Brogden and Sorkin, 1990 ) -was partially effective in a small clinical trial of childhood-onset TS (Bonnier, et al., 1999) . We predict ketanserin would block cortical-limbic glutamate output more weakly than ritanserin, a drug that could inhibit not just cortical glutamatergic neurons' 5-HT2a,c receptors and their output tics and urges (Sheldon and Aghajanian, 1991; Aghajanian, 1998, 1999) but also inhibit amygdalar glutamatergic neurons' 5-HT2c receptors and their output of tic-aggravating anxiety (Goetz, 1992; Gibson et al., 1994) . Bolstering that prediction, ritanserin counters serotonergic drug-induced tic-like and OC/craving-like symptoms (Willins and Meltzer, 1997; Ciccocioppo et al., 1999) .
Second, clinical studies of the other drugs bolster our data on their potential efficacy for TS and OC disorders: prazosin clinically is prescribed only as an antihypertensive drug, but alleviates alcohol craving , which is thought to involve CSTC circuits shared with OC-spectrum impulse control disorder (Grant et al., 2014) . Moxonidine likewise is clinically prescribed only as a centrally acting antihypertensive, but reduces rigidity in a hypodopaminergic mouse model of parkinsonism, supposedly by inhibiting STR IP MSN output (Tanabe et al., 2008 ) -which implies it should also reduce hyperdopaminergic or hyperglutamatergic tics by similarly inhibiting STR DP MSN output. Furthermore, in mice moxonidine is not only antihypertensive but also inhibits anxiety and anxiety-dependent OC behaviors (Taksande et al., 2010; Dixit et al., 2014) . Low-dose bromocriptine reduces human OC symptoms (Ceccherini-Nelli and Guazzelli, 1994 ), hence should be tested for at least TSþOCD. Furthermore, its specificity as a presynaptic D2 agonist may permit it to alleviate TS with more efficacy than that reported for mixed D1/D2 agonists with postsynaptic D1 agonist activity, like pergolide (Gilbert et al., 2000) .
Finally, we propose it would be fruitful to clinically examine the therapeutic potential of these and future proposed "hyperglutamatergic CSTC circuit" breaking drugs upon not only TS, TSþOCD, and OC/impulse-control disorders; but also upon all psychotic-spectrum disorders and psychomotor side effects of therapeutic drugs or drugs of abuse -all of which we suspect similarly necessitate hyperactive glutamate output from topographically-parallel forebrain CSTC circuit loops.
Conclusion
Tics and comorbid compulsions may be mediated, and in some etiologies triggered, by chronic and coincident efflux of somatosensory cortical/amygdalar glutamate and nigral DA onto target striatal direct and indirect pathway circuits. In such "hyperglutamatergic CSTC circuit" models -a circuit effect mimicked by D1CT-7 "Ticcy" transgenic mice -premonitory urges, tics, compulsions, impulses, cravings, obsessions, hallucinations, and their shared endophenotypes such as PPI/sensorimotor gating deficits, may be triggered by primary or secondary chronic forebrain glutamatergic hyperexcitation of the striatum and substantia nigra, with the latter hyperglutamatergic nigral effect permitting b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 -5 3 dopaminergic unbalancing of glutamate-excited striatal neurons' motion/urge-activating (direct) vs. motion/urge-suppressing (indirect) outputs, chronically favoring striatal direct pathway activation of motions and urges. Such symptoms would be counteracted not only by drugs that directly block forebrain glutamatergic neurons' output, but by antagonists of these neurons' co-expressed excitatory forebrain serotonin (ritanserin) and norepinephrine (prazosin) receptors; and by presynaptic agmatinergic or dopaminergic drugs that respectively would block the downstream glutamatetriggered target striatothalamic neurons' GABA output (moxonidine), or the downstream glutamate-triggered target nigrostriatal neurons' co-modulatory DA output (bromocriptine). Our observation that Ticcy mice's tics are alleviated by acute treatment with each of these four drug classes confirms the drugs may be "circuit-breaking" the mice's hyperglutamatergic CSTC tic-circuit. Our model merges prior glutamate, dopamine, serotonin, norepinephrine, and agmatine/imidazoline circuit models of tic and OC spectrum-disorders, and of related psychotic-spectrum disorders and psychotropic drug effects. Our findings suggest that the neuropotentiated D1CT-7 Ticcy transgenic mouse and its hyperglutamatergic CSTC circuit model will be valid for studying circuit alterations that mediate or underlie psychomotor diseases, and for designing and testing future clinical interventions, including new prospective drugs and cortical-limbic or striatal targeted therapies.
Experimental procedures
Animal subjects
30 adult Balb/c-inbred female wild-type control (C) mice and 32 adult Balb/c-inbred female hemizygous D1CT-7 ("Ticcy") transgenic (Tg) sibling mice were randomly assorted into four studies of drug effects on tic incidence and locomotion, using 7-9 Tg mice and 5-11C mice per study. The D1CT-7 mouse strain is available through JAX labs, Bar Harbor, ME, USA, as cryopreserved stock no. 008367, "C.Cg-Tg(DRD1-ctxA)7Burt/J mice" strain. Because Tg females breed and nurse poorly due to Tg-induced anxiogenic fleeing from males and overgrooming and biting of pups Nordstrom and Burton, 2002) , Tg males must be used as breeders to maintain the Ticcy mouse colony, while Tg females are used for drug studies. All animals were naive to behavioral or drug assays prior to testing, and experiments were carried out with the investigators blinded as to the animals' transgenic or control genotype status and drug injection status. All mice were housed in groups of 2-5 in a temperature-controlled room on a 12-h day-night cycle, allowed unrestricted access to food and water with the exception of testing times, and drug-treated and videotaped at the same daytime range of hours to control for the possibility of circadian fluctuation in drug response. Care was taken to ensure that breeding and study animals received no unnecessary discomfort. All animals were maintained and procedures were performed in accordance with the Animal Welfare Act and the NIH Guide for the Care 
Drugs and injections
Except where indicated, for each drug study mice in both genotype groups were administered stock solutions of drug or saline vehicle, 24 h apart, at the injection volumes and at the acute doses, as well as assayed behaviorally at post-injection times, that were previously reported to induce a maximal behavioral effect; and the behavioral observation of videotapes were performed blinded as to the animals' transgenic or control genotype status and drug or saline injection status, while observation counts were confirmed by a repeat observer. Ritanserin (Research Biochemicals International, Natick, MA, USA) was prepared as a stock solution (0.1 mg/ml ritanserin, 0.04% Tween-80 in saline) by suspending 10 mg drug in 2 ml of 2% Tween-80 followed by 50-fold dilution in saline vehicle (0.9% NaCl). All administrations of ritanserin or vehicle were delivered intraperitoneally (i.p.) in an injection volume of 10 ml/kg body weight. The 1 mg/kg i.p. ritanserin dosage was chosen for this study based on its reported efficacy in alleviating abnormal behaviors triggered via serotonin 5-HT2a receptors without any concomitant inhibition of spontaneous locomotor activity (Ninan and Kulkarni, 1998) , which we confirmed as described (see Results). Likewise, Tween-80/saline vehicles ranging in Tween-80 concentrations of up to 32% reportedly have no motor-inhibiting effects (Castro et al., 1995) , which we confirmed by comparison of both tics and locomotor activity levels in salineinjected vs. 0.04% Tween-80/saline-injected transgenic mice (not shown).
Prazosin hydrochloride was obtained from Research Biochemicals International (Natick, MA) and dissolved in 0.9% saline. The drug was administered in a volume of 10 ml/kg body weight, at a previously reported effective dosage of 3 mg/kg i.p. (Wellman and Davies, 1992; Wellman et al., 1997; Cheng and Kuo, 2003) , and was confirmed to have no locomotor suppressing effect (see Section 2). Moxonidine hydrochloride was obtained from Research Biochemicals International (Natick, MA) and dissolved in 0.9% saline. The drug was administered i.p. in a volume of 10 ml/ kg body weight, at a previously reported effective dosage of 0.5 mg/kg (Zhu et al., 1999) , and was confirmed to have no locomotor suppressing effect (see Section 2).
Bromocriptine methanesulfonate was obtained from Research Biochemicals International (Natick, MA) and dissolved in 0.9% saline. The drug was administered in a volume of 10 ml/kg body weight, at a previously reported effective (but also locomotor suppressing) dosage of 5 mg/kg i.p. that at 2 h post-injection was reported to act selectively on striatonigral presynaptic D2 autoreceptors (Jackson et al., 1988) , and was confirmed to confer both tic-inhibitory and mild locomotor suppressing effects (see Section 2).
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Tic behavior quantification
The incidence of tic-like behavior was determined in videotapes of transgenic vs. control non-transgenic littermate female mice. Tics were defined as any very brief (0.05-0.1 s, as determined by a duration of 1.5 to 3 frames in 30 fps videotape recordings) isolated head and/or body jerk or shake, other than those associated with acoustic startle or obvious shedding of litter visible on the coat. By this definition normal mice exhibit tic-like twitches only infrequently, compared to 3-to 5-fold more frequent tic-like twitches in D1CT-7 transgenic mice (Nordstrom and Burton, 2002) . The effect on tic incidence of vehicle vs. drug treatment was determined as the mean number of tics/15 min time unit (tics/15 min) in transgenic or control mice observed over a 15 min period beginning 30 min after either vehicle or drug injection and 15 min after introduction of the mice into a new cage (i.e., after a 15 min cage habituation period), with these exceptions: 1) In the ritanserin study, 15 min cage habituation was omitted to avoid confounding a reported anxiolytic effect of ritanserin (Gao and Cutler, 1993) with any potential anxiolytic effect of cage habituation, while tic counts (and midline crossings, as described below in Section 5.4) were instead observed and analyzed over the entire 30 min period beginning 30 min after either vehicle or drug injection -but because subsequent analysis confirmed there was no significant effect of 15 min cage habituation upon control or transgenic tic incidence or midline crossings in the presence or absence of ritanserin treatment (not shown), the tic and midline crossing data are displayed in the standard 15-min time unit; 2) In the bromocriptine study, the post-injection observations commenced not 30 min but two hours after injection of bromocriptine, to match the prior reported time of maximal presynaptic agonist action of the drug in mice (Jackson et al., 1988) , while pre-injection observational data was obtained 15 min prior to bromocriptine injection with no saline vehicle injection, likewise to match the prior reported drug design. Videotapes and/or drug and vehicle samples were coded to blind observers to the mice's genotype and drug-injection status, and data were independently logged by at least two independent observers (raters), with excellent interrater reliability confirmed by an Intraclass Correlation Coefficient (ICC)40.8.
Locomotion behavior quantification
To measure spontaneous locomotor activity levels during the observation periods the same videotapes as described above were analyzed for the number of cage-midline crossings (the observed number of locomotion-dependent cage midline incursions, which reproduces an automated beam-break design, as described by Nordstrom and Burton (2002) . Data were displayed as the number of midline crossings/15 min. At least two observers blinded to subject genotype and treatment independently logged the numbers of midline crossings from the original videotapes, and confirmed excellent interrater reliability of ICC40.8. Additionally, for the bromocriptine study, because this dopaminergic motor outputinhibiting drug (unlike ritanserin, prazosin and moxonidine) is reported to also diminish mouse locomotion (Jackson et al., 1988) , a more comprehensive behavioral analysis of this drug's locomotion suppressing effects was also performed, as described below (Section 5.5).
Behavioral waveform display analysis of bromocriptine treated mice
Behavioral waveform display analysis was performed as previously described (Campbell et al., 1998) . Briefly, the above-described videotapes of drug-naive D1CT-7 transgenic or control female littermates were continuously observed for 15 min prior to bromocriptine injection and 2 h post-injection, in each case after 15 min of habituation to a new cage. EthoMac (v1.10, © The University of Minnesota) software was used for behavioral state entry, and for calculation and tabulation of behavioral state event timing, number, and duration. (EthoMac-analogous commercial software is available for Windows platforms as "Observer XT," Noldus Information Technologies, The Netherlands.) Scored behaviors included: 1) climbing-leaping (animal standing on its hind paws in the corner of the cage moving at least three limbs); 2) still (remaining in one position with an occasional head movement); 3) rear; 4) gnaw (gnawing against the side of the Plexiglas cage); 5) locomotion (each such event yielding a smaller number of cage midline crossings, as described above in Section 5.4); 6) dig (into the sawdust bedding); 7) groom; 8) hang (from the wire bar cage lid); 9) eat (bedding picked from the cage bottom and put into the mouth); 10) sniff; 11) other (any activity that does not fit into the previous categories). The total observer-scored number of locomotion events for each mouse under each post-bromocriptine observation period, as tabulated by the EthoMac logs, was confirmed by at least one independent, genotype-and treatment-blinded observer from original coded videotapes, confirmed to have ICC40.8 interrater reliability, then statistically compared for the extent of bromocriptine and genotype effects and displayed as the mean number of locomotion events/15 min.
Statistical analyses
Overall statistical significance of a ritanserin, prazosin, moxonidine, or bromocriptine drug (within-groups) effect, Ticcy transgenic (Tg) vs. control (C) wild-type genotype (betweengroups) effect, or a drug by genotype interaction, was determined in Statview 4.5 (Abacus Corp., Berkeley CA, USA) by initial repeated-measures analysis of variance (repeatedmeasures ANOVA) on both tic and locomotion behavioral measures, followed by individual between-group unpaired, two-tailed Student's t-test comparisons of genotype effect and within-group paired, two-tailed Student's t-test comparisons of drug effect, with significance assumed at Po0.05, for parametrically-distributed locomotion data; or individual between-group Mann-Whitney U-tests of genotype effect and within-group Wilcoxon Signed Rank tests of drug effect, with significance assumed at tied Po0.05, for the nonparametrically-distributed tic incidence data. Because elevated tic counts in the Ticcy genotype population epigenetically sort into a non-parametric biphasic distribution caused by the presence within the Ticcy group of betweenindividuals (epigenetically) variable but within-individuals consistent "super ( $ 6-fold) ticcers" vs. "elevated ( $3-fold) ticcers," the use of an individual repeated-measures drug design is necessitated, as performed by Nordstrom and Burton (2002) and herein. In such a design, each subjects' behavior is tested both with and without drug injection, which permits drug effects to be tested reliably on such populations even though the Tg group mean tic count and standard error will vary between separate drug studies, based on each Tg group's proportion of "super-ticcers." All data were expressed as the mean plus standard error of the mean (SEM) of the number of tics per 15 min, cage midline crossings per 15 min, or locomotion events per 15 min, occurring during the videotaped windows of observation.
